Crossmark Global Holdings Inc. Reduces Position in argenx SE (NASDAQ:ARGX)

Crossmark Global Holdings Inc. lessened its holdings in shares of argenx SE (NASDAQ:ARGXFree Report) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,179 shares of the company’s stock after selling 160 shares during the period. Crossmark Global Holdings Inc.’s holdings in argenx were worth $1,970,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Parkside Financial Bank & Trust purchased a new position in shares of argenx during the third quarter valued at approximately $28,000. FNY Investment Advisers LLC purchased a new stake in shares of argenx in the fourth quarter valued at approximately $38,000. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of argenx in the fourth quarter valued at approximately $60,000. Principal Securities Inc. purchased a new stake in shares of argenx in the fourth quarter valued at approximately $99,000. Finally, Toronto Dominion Bank boosted its holdings in shares of argenx by 174.2% in the third quarter. Toronto Dominion Bank now owns 266 shares of the company’s stock valued at $131,000 after purchasing an additional 169 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of ARGX opened at $375.81 on Friday. The firm has a market capitalization of $22.33 billion, a PE ratio of -66.40 and a beta of 0.65. argenx SE has a 1-year low of $327.73 and a 1-year high of $550.76. The company’s fifty day moving average price is $376.66 and its 200-day moving average price is $394.44.

argenx (NASDAQ:ARGXGet Free Report) last announced its quarterly earnings data on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.33). argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. The company had revenue of $412.51 million for the quarter, compared to analysts’ expectations of $404.03 million. During the same period last year, the firm earned ($0.52) earnings per share. As a group, research analysts anticipate that argenx SE will post -2.75 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on ARGX shares. Robert W. Baird lowered their price target on argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a report on Friday, March 1st. Truist Financial boosted their price objective on shares of argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Wells Fargo & Company boosted their price objective on shares of argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 20th. Morgan Stanley reduced their price objective on shares of argenx from $515.00 to $510.00 and set an “overweight” rating for the company in a research note on Tuesday, May 28th. Finally, Wolfe Research began coverage on shares of argenx in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $520.68.

View Our Latest Analysis on ARGX

argenx Profile

(Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Read More

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.